Thomas Schwieterman, MD, and Randy Wexler, MD, MPH, FAAFP, discuss the key role blood pressure measurement plays in both disease management strategies and metrics for value-based care models — plus, how doctors can improve measurement positioning and protocol.
Presented by: Thomas D. Schwieterman, M.D., MBA & Randy Wexler MD, MPH, FAAFP
Thomas D. Schwieterman, M.D., MBA
Vice President of Clinical Affairs and
Chief Medical Officer
As Vice President of Clinical Affairs and Chief Medical Officer for Midmark Corporation, Dr. Tom Schwieterman has a profound understanding of the trends and issues driving the healthcare industry through significant change and evolution. His experience as a private practice physician for 12 years in a rural community gives him a unique perspective on problems and opportunities facing physician practices, especially at the point of care.
Randy Wexler MD, MPH, FAAFP
Professor of Medicine
Vice Chair for Academics
Ohio State University
Randy is a Professor of Family Medicine and Vice Chair for Academics at the Ohio State University. He received his medical degree from Wright State University, and his MPH from the Ohio State University College of Public Health. His research interests include improved cardiovascular care in the primary care setting and evolution of value-based health care models. Dr. Wexler has received research funding from NIH, AHRQ, and Ohio Medicaid, as well as various Foundations.
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More